D
Akebia Therapeutics, Inc. AKBA
$1.59 $0.021.27% NASDAQ
Recommendation
Prev Close
$1.57
Volume
1,286,365
Avg Vol (90D)
4,220,160
Market Cap
$416.62M
Dividend & Yield
--
52-Week Range
$1.45 - $4.08
P/E (TTM)
--
EPS (TTM)
-$0.08
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Akebia Therapeutics (NASDAQ:AKBA) Receives Buy Rating from BTIG Research
12/3/2025 - MarketBeat
Akebia Therapeutics (NASDAQ:AKBA) Receives "Buy" Rating from HC Wainwright
12/3/2025 - MarketBeat
Analysts Offer Insights on Healthcare Companies: NRX Pharmaceuticals (NRXP), Akebia Therapeutics (AKBA) and Ionis Pharmaceuticals (IONS)
12/3/2025 - TipRanks Financial Blog
BTIG Reiterates Buy Rating for Akebia Therapeutics (AKBA) AKBA Stock News
12/2/2025 - GuruFocus
Cyclerion Receives Milestone Payment from Akebia
12/1/2025 - TipRanks Financial Blog
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/1/2025 - GuruFocus
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/1/2025 - Globe Newswire
Akebia Therapeutics (AKBA) Expands Pipeline with Rare Kidney Disease Treatments
12/1/2025 - GuruFocus
Akebia Therapeutics (AKBA) Acquires Phase 2 Drug from Q32 Bio
12/1/2025 - GuruFocus
Akebia Therapeutics (AKBA) Acquires Phase 2 Inhibitor ADX-097
12/1/2025 - GuruFocus
Akebia Therapeutics Acquires Global Rights to ADX-097
12/1/2025 - TipRanks Financial Blog
Q32 Bio Sells ADX-097 to Akebia Therapeutics
12/1/2025 - TipRanks Financial Blog
Akebia Therapeutics announces establishment of rare kidney disease pipeline
12/1/2025 - The Fly
Q32 Bio Sells Complement Inhibitor ADX-097
12/1/2025 - PR Newswire
Akebia Announces Establishment of Rare Kidney Disease Pipeline
12/1/2025 - Globe Newswire
akebia pays 12m complement q32 bio centerpiece rare kidney disease pipeline
12/1/2025 - FierceBiotech.com - Biotech
Akebia Therapeutics (NASDAQ:AKBA) Cut to "Buy" at Wall Street Zen
12/1/2025 - Ticker Report
Akebia Therapeutics (NASDAQ:AKBA) Downgraded by Wall Street Zen to "Buy"
11/29/2025 - MarketBeat
Akebia Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference
11/24/2025 - GuruFocus
Akebia Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference
11/24/2025 - Globe Newswire
Akebia Therapeutics Amends License Agreement with MEDICE
11/17/2025 - TipRanks Financial Blog
Q2 Earnings Forecast for AKBA Issued By HC Wainwright
11/14/2025 - MarketBeat
Implied Volatility Surging for Akebia Therapeutics Stock Options
11/13/2025 - Zacks Investment Research
Analysts Offer Predictions for AKBA Q1 Earnings
11/13/2025 - MarketBeat
Why Akebia Therapeutics (AKBA) Is Up After Strong Q3 Earnings and Promising Vafseo Kidney Data
11/13/2025 - Simply Wall St
Income Statement
Total Revenue (TTM)
$225.07M
EBITDA (TTM)
$32.51M
EBIT (TTM)
$22.22M
Net Income (TTM)
-$15.91M
Balance Sheet
Total Assets (Q)
$364.15M
Total Debt (Q)
$199.01M
Total Liabilities (Q)
$322.56M
Book Value Per Share (Q)
$0.1568
Cash Flow
Cash from Operations (TTM)
$32.40M
Cash from Investing (TTM)
-$51.00K
Cash from Financing (TTM)
$100.10M
Net Change in Cash (TTM)
$132.45M
Filings
Filing Date
Monday, November 10, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Week of Mar 9 and 13 (est)
Price History
Loading...
Beta
1.22
7-Day Total Return
0.31%
30-Day Total Return
-46.66%
60-Day Total Return
-45.56%
90-Day Total Return
-54.56%
Year to Date Total Return
-16.05%
1-Year Total Return
-21.43%
2-Year Total Return
38.70%
3-Year Total Return
445.86%
5-Year Total Return
-48.21%
52-week Low
Dec 02, 2025 - $1.45
52-week High
Jul 11, 2025 - $4.08
Valuation
Market Cap
$416.62M - Small Cap
Enterprise Value
$449.19M
Price/Sales (TTM)
1.91
Price/Book (Q)
10.01
Dividends and Shares
Shares Outstanding
274.37
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.akebia.com
Phone Number
617 871 2098
Address
245 First Street
Cambridge, MA 02142
Country
United States
Year Founded
2007
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo... more
NASDAQ 12/04/2025 2:21PM Eastern Quotes delayed